Additional Relevant Details

• Top-line findings from first 17 patients enrolled in this trial (“Low Dose Cohort”)
  • Dosing: each patient received 100 mg/day of relacorilant for four weeks, then 150 mg/day for four weeks, then 200 mg/day for four weeks
  • Statistically significant, dose-dependent improvements in glucose tolerance and serum osteocalcin (a marker of bone growth suppressed by excess cortisol activity)
  • Five millimeters or greater reduction in blood pressure in 45 percent of patients with uncontrolled hypertension
  • Noevidenceofprogesteronereceptoraffinity;noseriousadverseevents